EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Twenty‐year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer

Orit Kaidar-Person iD, Caroline G Weltens iD, Catherine Fortpied, Luc J E E Scheijmans iD, Carine Y Kirkove iD, Volker Budach iD, Karine Peignaux-Casasnovas iD, Mariacarla Valli iD, Max Peters iD, Femke van der Leij iD, Sofia Rivera, Nicola Weidner und 13 weitere

CA: A Cancer Journal for Clinicians · 2026-05 · 76 (3)

DOI: 10.3322/caac.70082 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 16.05.2026. Verfasst von Orit Kaidar-Person und 24 weiteren Autor:innen. Beteiligte Einrichtung: Breast Radiation Unit, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymphatic Irradiation, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kom op tegen Kanker, EORTC Cancer Research Fund, KWF Kanker Bestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

European Organization for Research and Treatment of Cancer trial EORTC 22922/10925 evaluated internal mammary and medial supraclavicular (IM‐MS) lymph node irradiation (IM‐MS‐RT) in patients with stage I–III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors regardless of nodal involvement. The primary end point was overall survival, secondary end points were disease‐free survival, distant metastases‐free survival, breast cancer mortality, and any breast recurrence. Between 1996 and 2004, 4004 patients were randomized. The median patient age was 54 years. At a median follow‐up of 22.2 years, 1550 (38.7%) patients died, of whom 796 (51.4%) died from breast cancer. At 20 years, the overall survival rate was 61.8% in the control group versus 61.0% in the IM‐MS‐RT group (hazard ratio [HR], 1.00; p = .967); the disease‐free survival rate was 49.0% versus 48.2%, respectively (HR, 0.97; p = .515); and the distant metastases‐free survival rate was 59.8% versus 58.9%, respectively (HR, 0.97; p = .578). The breast cancer mortality rate was 22.4% in the control group and 18.6% in the IM‐MS‐RT group (HR, 0.82; p = .006), whereas the rate of deaths not from breast cancer or from unknown causes was 15.8% versus 20.4%, respectively (HR, 1.26; p = .002). Lung fibrosis, cardiac fibrosis, and cardiac diseases were more frequent after IM‐MS‐RT versus no IM‐MS‐RT (6.3% vs. 3.2%, 2.7% vs. 1.7%. and 15.2% vs. 11.7%, respectively); and the rates of severe cardiac and lung morbidities (scores of 3 or 4) were 1.9% versus 1.7% and 0.3% versus 0.0%, respectively. Breast cancer mortality at 20 years was statistically significantly lower after IM‐MS‐RT, but deaths not from breast cancer increased after 15 years, resulting in no long‐term benefit of IM‐MS‐RT on overall survival. Therefore, the authors strongly call for very long‐term follow‐up of treatments for prognostically favorable cancers such as breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymphatic IrradiationLymph NodesHumansFemaleMiddle AgedNeoplasm StagingLymphatic MetastasisAdultAgedDisease-Free SurvivalNeoplasm Recurrence, LocalFollow-Up StudiesRadiotherapy, AdjuvantSurvival Rate

Stichwörter der Autor:innen

European Organization for Research and Treatment of Cancer (EORTC)breast cancerinternal mammarylymph nodesradiotherapyrandomized trial

Autor:innen und Institutionen

  • Breast Radiation Unit, Sheba Medical Center, Ramat Gan, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory of Experimental Radiation Oncology, Katholieke Universiteit te Leuven, Leuven, Belgium.
  • European Organization for Research and Treatment of Cancer, Brussels, Belgium.
  • Department of Radiation Oncology, Institute Verbeeten, Tilburg, Netherlands.

ORCID-Profile: Orit Kaidar-Person, Caroline G Weltens, Luc J E E Scheijmans, Carine Y Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Mariacarla Valli, Max Peters, Femke van der Leij, Desirée H J G van den Bongard, Roxolyana Abdah-Bortnyak, Adinda Baten, Lydia Champezou, Philip M P Poortmans

Förderung

  • Kom op tegen Kanker
  • EORTC Cancer Research Fund
  • KWF Kanker Bestrijding
  • Ligue Contre le Cancer

Zitieren

APA

Kaidar-Person, O., Weltens, C. G., Fortpied, C., Scheijmans, L. J. E. E., Kirkove, C. Y., Budach, V., Peignaux-Casasnovas, K., Valli, M., Peters, M., van der Leij, F., Rivera, S., Weidner, N., van den Bongard, D. H. J. G., Linsenmeier, C., Abdah-Bortnyak, R., Hosni, S., Koiter, E., Engelen, A. M., Baten, A., …, & European Organization for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups (2026). Twenty‐year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer. CA: A Cancer Journal for Clinicians, 76(3). https://doi.org/10.3322/caac.70082

Vancouver

Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, et al. Twenty‐year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer. CA: A Cancer Journal for Clinicians. 2026;76(3). doi:10.3322/caac.70082

BibTeX
@article{KaidarPerson2026,
  author = {Kaidar-Person, Orit and Weltens, Caroline G and Fortpied, Catherine and Scheijmans, Luc J E E and Kirkove, Carine Y and Budach, Volker and Peignaux-Casasnovas, Karine and Valli, Mariacarla and Peters, Max and van der Leij, Femke and Rivera, Sofia and Weidner, Nicola and van den Bongard, Desirée H J G and Linsenmeier, Claudia and Abdah-Bortnyak, Roxolyana and Hosni, Shaymaa and Koiter, Eveline and Engelen, Antoine M and Baten, Adinda and Champezou, Lydia and Fourquet, Alain and Bartelink, Harry G M M and Struikmans, Henk and Poortmans, Philip M P and European Organization for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups, European Organization for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups},
  title = {Twenty‐year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {3},
  doi = {10.3322/caac.70082}
}
Kostenlos starten →